Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes
    STROKE ALERT

    Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes

    April 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    In Patients with Intracerebral Hemorrhage, Intensive Lowering of Blood Pressure Does Not Improve Outcome

    In Patients with Intracerebral Hemorrhage, Intensive Lowering of Blood Pressure Does Not Improve Outcome

    Tranexamic Acid and Outcomes in Patients with Moderate or Severe TBI

    Related Products

    Alzheimer’s Disease: What the Primary Care Physician Needs to Know

    All Access Subscription: Online

    Keywords

    Hemorrhage

    acid

    intracerebral

    tranexamic

    hematoma

    neurological

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, New York Presbyterian/Weill Cornell Medical College

    SOURCE: Meretoja A, Yassi N, Wu TY, et al. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): A multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2020;19:980-987.

    Primary intracerebral hemorrhage is a major cause of severe neurological disability and carries a high rate of death. Worldwide, it comprises 5% of all human deaths. Patients are treated in multidisciplinary specialized stroke units and neurological intensive care units, with the best possible results, but there are no specific, targeted therapies that are evidence-based and have shown benefit in the treatment of these patients. The major determinants of survival and clinical outcome are the patient’s age, level of consciousness at onset, and volume of the hematoma. In addition, it has been demonstrated in multiple studies that the hematoma size increases over the first several hours and up to 24 hours. One approach to therapy has been to prevent hematoma growth by administering a hemostatic agent. Recombinant activated coagulation factor VII was tested in two large trials with 1,240 patients treated within four hours of symptom onset, without showing a significant benefit in outcomes. Tranexamic acid was tested in a study of 2,325 patients with intracerebral hemorrhage within eight hours of symptom onset, but again, did not significantly improve neurological outcome.

    The current investigators of the STOP-AUST trial led a prospective, double-blind, randomized, placebo-controlled Phase II trial at 13 stroke centers in Australia, Finland, and Taiwan to determine if administration of tranexamic acid within four and a half hours of symptom onset would reduce hematoma growth and have an effect on neurological outcome. Patients were eligible to be enrolled if they were 18 years of age or older with an acute intracerebral hemorrhage, a Glasgow Coma Scale score > 7, intracerebral brain hemorrhage (ICH) volume less than 70 mL, no secondary cause of hemorrhage, no thromboembolic events in the previous 12 months, no planned surgery, no use of anticoagulants, and the presence of contrast extravasation on computed tomography angiography (spot sign). Infusion of tranexamic acid had to be started within four and a half hours of symptom onset. The primary outcome was growth of the intracerebral hemorrhage at 24 hours. A total of 100 participants were enrolled and randomly assigned to tranexamic acid treatment or placebo. There were 50 participants in each group. The median age was 71 years and the median intracerebral hemorrhage volume was 14.6 mL. The primary outcome, which was growth of hemorrhage at 24 hours, was not significantly different between the two groups. Fifty-two percent of patients in the placebo group and 44% in the tranexamic acid group had intracerebral hemorrhage growth of greater than 33% at 24 hours. There was no difference between the groups in mortality or thromboembolic complications. Although this study did not demonstrate benefit of treatment with tranexamic acid, the investigators suggested that earlier treatment should be studied and might be of benefit.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 8) - April 2021
    April 1, 2021

    Table Of Contents

    Phospho-Tau217 Blood Biomarker May Help to Diagnose Early Alzheimer’s Disease

    Cognitive Deficits in Patients Recovering from COVID-19

    Polyradiculoneuropathy from Immune Checkpoint Inhibitors

    Brain Cancer and Brain Injury Drive Systemic Immunosuppression

    Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion

    Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes

    Atorvastatin and Low-Dose Dexamethasone for Treatment of Chronic Subdural Hematoma

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Dr. Isaacson (author) reports he is a consultant for Genentech/Roche and Biogen, Dr. Rubin (author) reports he is a consultant for Merck Sharpe & Dohme Corp., and Dr. Noch (author) reports he is a stockholder in Destroke, Inc. All of the relevant financial relationships listed for these individuals have been mitigated. None of the remaining authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing